| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8769185 | Actas Urológicas Españolas | 2017 | 9 Pages |
Abstract
In high-risk renal-cell carcinoma after nephrectomy, sunitinb has been considered as treatment choice. In localized prostate cancer, prostate-cancer-specific mortality was low irrespective of the treatment assigned (active monitoring, radical prostatectomy and external-beam radiotherapy). In metastatic castration-resistant prostate cancer new results of treatment with enzalutamide and abiraterone has been published, wich have been shown beneficial effects in metastatic and no metastatic patients.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
F. Gómez-Veiga, A. Alcaraz-Asensio, J. Burgos-Revilla, J.M. Cózar-Olmo,